Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905)

British Journal of Cancer

Volumn 90, Issue 6, 2004, Pages 1216-1221

  Dales, J P ^a   Garcia, S ^a   Carpentier, S ^a   Andrac, L ^a   Ramuz, O ^a   Lavaut, M N ^a   Allasia, C ^a   Bonnier, P ^b   Taranger Charpin, C ^a  

^a HÔPITAL NORD   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Breast cancer; CD105; Prognosis; Tie 2 Tek; VEGF R1; VEGF R2

Indexed keywords

ANGIOPOIETIN RECEPTOR; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 5; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATIENT MONITORING; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SAMPLING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, TIE-2; RECEPTORS, CELL SURFACE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 1942437510     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601452     Document Type: Article

References (38)

1. Altman DG, Lausen B, Sauerberi W, Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
2. Bloom HG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
3. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86-91
4. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L (1995) CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 103: 443-448
5. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN, Allasia C (1997) CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas. Correlation with patient follow-up. Am J Clin Pathol 107: 534-541
6. Charpin C, Martin PM, Devictor B, Lavaut MN, Habib MC (1988) Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. Cancer Res 48: 1578-1586
7. Ellis LM, Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 14: 2451-2460
8. Elston CN, Ellis IO (1991) Pathological prognostic factors in breast cancer, I: the value of the histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410
9. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763
10. Folkman J, D'Amore PA (1996) Blood vessel formation: what is its molecular basis? Cell 87: 1153-1155
11. Fonsatti E, Delvecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M (2001) Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188: 1-7
12. Fox SB, Gasparini G, Harris AL (2001) Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2: 278-289
13. Gasparini G (1996a) Angiogenesis research up to 1996: a commentary on the state of art and suggestions for future studies. Eur J Cancer 14: 2379-2385
14. Gasparini G (1996b) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A: 2485-2493
15. Gasparini G, Harris AL (1995) Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13: 765-782
16. Hatva E, Kaipainen A, Mentula P, Jaaskekainen J, Paetau A, Haltia M, Alitalo K (1995) Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146: 368-378
17. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Greenall M, Stepniewska K, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124
18. Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S, Alitalo K (1994) Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 54: 6571-6577
19. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred M (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861
20. Kumar P, Wang JM, Bernabeu C (1996) CD105 and angiogenesis. J Pathol 178: 363-366
21. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG (1998) Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 95: 8829-8834
22. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100: 2072-2078
23. Maisonpierre PC, Goldfarb M, Yancopoulos GD, Gao G (1993) Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 8: 1631-1637
24. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK (1999) Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5: 371-382
25. Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895-898
26. Partanen J, Armstrong E, Makela TP, Korhonen J, Sandberg M, Renkonen R, Knuutila S, Huebner K, Alitalo K (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 12: 1698-1707
27. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Sankar S, Trogan E (1998) Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 77: 51-56
28. Salven P, Joensuu H, Heikkila P, Matikainen MT, Wasenius VM, Alanko A, Alitalo K (1996) Endothelial tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74: 69-72
29. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M (1997) Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3: 1031-1044
30. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marne D, Martiny-Baron G (1999) Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by intering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59: 3185-3191
31. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968
32. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T (1996) Clinical significance of the determination of angiogenic factors. Eur J Cancer 32A: 2513-2519
33. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484
34. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19
35. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887
36. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324: 1-8
37. Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H (2001) Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir 143: 159-166
38. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M, Saito Y (2000) Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 77: 413-418